J&J's Cordis discloses promising two-year data for AAA stent; Boston Scientific readies Q4 earnings;

@FierceMedDev: Montagu Private Equity grabs Rexam's healthcare packaging arm for $805M. Story | Follow @FierceMedDev

@MarkHFierce: ArthroCare, stained by a federal fraud scandal, gets a fresh start with Smith & Nephew's planned $1.7B acquisition. More | Follow @MarkHFierce

@MichaelGFierce: Study reports success in targeted therapy for common form of lung cancer. Report | Follow @MichaelGFierce

@EmilyWFierce: Given Imaging scores FDA seal of approval for PillCam COLON device. News | Follow @EmilyWFierce

> Boston Scientific ($BSX), which has shown some signs of a turnaround, plans to announce its 2013 fourth-quarter earnings on Tuesday, Feb. 4. Item

> Johnson & Johnson's ($JNJ) Cordis arm said it generated encouraging two-year clinical trial results involving its Incraft AAA Stent Graft System to treat abdominal aortic aneurysms. Item

> North Carolina-based Sapheon gained Health Canada approval for a medical adhesive designed to treat varicose veins. Story

> Ben Franklin Technology Partners in Southeastern Pennsylvania has invested $2 million in a number of early-stage med tech, high-tech and life sciences companies. Story

> The wearable medical devices market is expected to be worth $5.8 billion globally by 2019, according to a report from Transparency Market Research. Item

Biotech News

@FierceBiotech: Buzz: GlaxoSmithKline prepares to unveil a new PhIII lineup. Story | Follow @FierceBiotech

@JohnCFierce: Eager biotechs (9!) crowd into Wall Street this week with $500M in IPO pitches. News | Follow @JohnCFierce

@DamianFierce: Portola takes its 'breakthrough' bleeding drug to PhIII with Bayer, J&J in tow. Read | Follow @DamianFierce

@EmilyMFierce: Merck halts drug testing on chimpanzees. Story | Follow @EmilyMFierce

> Merck turns to Ablynx to hunt cancer immunotherapies in potential $2.3B deal.& News

> Pfizer's promising results for palbociclib stir talk of early approval push. More

Pharma News

@FiercePharma: WSJ: Scientist's lawsuit accuses AstraZeneca of fudging Brilinta study. Story | Follow @FiercePharma

@TracyStaton: Biogen Idec's Tecfidera nabs EU approval for first-line MS treatment. Rollout TK. More | Follow @TracyStaton

@EricPFierce: The FDA says it will take a look at the heart risks of testosterone boosting drugs. Report | Follow @EricPFierce

@CarlyHFierce: More Humira sales gains help AbbVie meet forecasts. News | Follow @CarlyHFierce

> WSJ: Scientist's lawsuit accuses AstraZeneca of fudging Brilinta study. More

> Suitors size up Merck's consumer unit for potential $10B deal: Reuters. Story

> Valeant adds to skin-care quiver with $475M PreCision Dermatology buy. News

CRO News

> Parexel rebounds from a shaky fall as sales jump 15%. Article

> Indian CRO GVK buys its way into biologics with Aragen deal. Story

> Ergomed cuts a risk-sharing deal on Ferrer's insomnia drug. News

> InVentiv looks to corner the market on mid-size biotechs. Story

> Growing Novotech makes its way into Africa. Article

> Algorithme doubles down on complex trials with latest addition. Brief

Biotech IT News

> J&J hands Yale the keys to its clinical trial data vault. Story

> Dassault makes a $750M play for Accelrys to expand into R&D software. Article

> Infosys co-founder backs an Indian brain computing center. News

> Bioinformatics skills help Stanford to a $40M genomics grant. Story

> The FDA's Mini-Sentinel healthcare surveillance database is growing quickly. Article

> Empiriko teams up to scale liver-mimicking technology. Brief

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.